Cargando…

Infections Simulating Immune Checkpoint Inhibitor Toxicities: Uncommon and Deceptive

Use of immune checkpoint inhibitors (ICIs), a revolutionary treatment in modern oncology, is frequently complicated by immune-related adverse events (irAEs), which can be confused with infections, and vice versa, thus complicating management decisions. In this study, we review the published cases of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gudiol, Carlota, Hicklen, Rachel S, Okhyusen, Pablo C, Malek, Alexandre E, Kontoyiannis, Dimitrios P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679804/ https://www.ncbi.nlm.nih.gov/pubmed/36420059 http://dx.doi.org/10.1093/ofid/ofac570

Ejemplares similares

Invasive Fungal Infections at Presentation of Untreated Hematologic Malignancies: Rare and Elusive
por: Spallone, Amy, et al.
Publicado: (2020)

Cat Scratch Disease as a Mimicker of Malignancy
por: Dhal, Udit, et al.
Publicado: (2021)

Insect Bite–Associated Invasive Fungal Infections
por: Kontoyiannis, Panayiotis D, et al.
Publicado: (2019)

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
por: Sisi, Monia, et al.
Publicado: (2023)

Hypoparathyroidism: An Uncommon Complication Associated With Immune Checkpoint Inhibitor Therapy
por: El Kawkgi, Omar M., et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for the Therapy of Thymoma
por: Quilez, Alicia, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors: Common Questions About Uncommon Adverse Events
por: Kottschade, Lisa
Publicado: (2021)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

Management of Immune Checkpoint Inhibitor Toxicities
por: Durrechou, Quentin, et al.
Publicado: (2020)

Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions
por: Wurster, Sebastian, et al.
Publicado: (2022)

Recurrence of Hypophysitis After Immune Checkpoint Inhibitor Rechallenge
por: Park, Benjamin C, et al.
Publicado: (2022)

1410. Isoniazid Therapy for Latent Tuberculosis Infection in Patients with Cancer Treated with Checkpoint Inhibitors Immunotherapy
por: Malek, Alexandre, et al.
Publicado: (2021)

Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
por: Albarrán, Víctor, et al.
Publicado: (2022)

Neutropenic Enterocolitis: An Uncommon, but Fearsome Complication of Leukemia
por: Babakhanlou, Rodrick, et al.
Publicado: (2023)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

1769. The Impact of Checkpoint Inhibitor Immunotherapy on Infections in Lung Cancer Patients
por: Malek, Alexandre, et al.
Publicado: (2019)

Seronegative antibody‐mediated neurology after immune checkpoint inhibitors
por: Wilson, Robert, et al.
Publicado: (2018)

Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia
por: Takamatsu, Koutaro, et al.
Publicado: (2018)

Immune checkpoint inhibitor in recurrent hypermutated glioblastoma with POLE mutation
por: Sathornsumetee, Sith, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors’ Associated Renal Toxicity: A Series of 12 Cases
por: Palamaris, Kostas, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
por: Bylsma, Sophia, et al.
Publicado: (2022)

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
por: Shalata, Walid, et al.
Publicado: (2021)

Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors
por: de Andrea, Carlos Eduardo, et al.
Publicado: (2020)

Immune checkpoint inhibitor‐induced enteritis assessed using capsule endoscopy
por: Otagiri, Shinsuke, et al.
Publicado: (2020)

Immune checkpoint inhibitor‐related gastritis in a patient with metastatic melanoma
por: Sugiyama, Yuya, et al.
Publicado: (2021)

Risk of COVID‐19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Klebanov, Nikolai, et al.
Publicado: (2021)

Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis
por: Masi, Gianvito, et al.
Publicado: (2023)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist
por: Tattersall, Ian William, et al.
Publicado: (2020)

Immune-checkpoint inhibitors: long-term implications of toxicity
por: Johnson, Douglas B., et al.
Publicado: (2022)

Imaging features of toxicities associated with immune checkpoint inhibitors
por: Gosangi, Babina, et al.
Publicado: (2022)

Management of pulmonary toxicity associated with immune checkpoint inhibitors
por: Delaunay, Myriam, et al.
Publicado: (2019)

Imaging assessment of toxicity related to immune checkpoint inhibitors
por: Berz, Antonia M., et al.
Publicado: (2023)

Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
por: Fujita, Kohei, et al.
Publicado: (2020)

Acquired Coagulopathy With Immune Checkpoint Inhibitors: An Underrecognized Association Between Inflammation and Coagulation
por: Joseph, Jacinth J., et al.
Publicado: (2020)

Analysing Deception in Witness Memory through Linguistic Styles in Spontaneous Language
por: Solà-Sales, Sara, et al.
Publicado: (2023)

Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
por: Isawa, Tsuyoshi, et al.
Publicado: (2022)

Clinical Presentations and Outcomes of Patients Receiving Immune Checkpoint Inhibitors Presenting to the Emergency Department
por: Castillo, Richmond M., et al.
Publicado: (2021)

Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms
por: Rhee, John Y, et al.
Publicado: (2022)

Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy
por: Widmann, Gerlig, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_60lhusm67u68jcevvmicggtc91